18 Oct 15

Neel is also a Professor, Department of Medical Biophysics, University of Toronto and holds a Canada Research Chair in Cell Signaling. – By studying two of the most frequently mutated pathways in cancer, discerning the mechanism by which they cause congenital disease, and treating two of these disorders that have identified with different drugs, we are potential therapeutic targets for human disease, says Dr. this is what is personalized medicine is: understanding in detail how to mutations mutations diseases, and then targeted the mutations appropriately to tailor individual treatment. .. The findings are available online in advance of the March issue of the Journal of Clinical Investigation published.Both studies were of UHN Dr. Benjamin Neel, Director, Ontario Cancer Institute, ell Family Cancer Research Institute belong merged.

Demonstrated in two separate but related studies at the University Health Network , Toronto, and Beth Israel Deaconess Medical Center , two drugs two drugs – one already approved how an immunosuppressant, the other being as tested could prevent an anti-cancer agent and reverse HCM in mouse models of congenital heart disease.Royal Society of log Biology LettersW Proceedings of of the Royal Society flagship model of biological trade magazine dealing with of rapid published and length dissemination of high quality research projects, ratings and comments and answer papers. The scope of the journal is versatile and is especially strong in biological organism.